Literature DB >> 3223331

Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.

W Danielczyk1, M Streifler, C Konradi, P Riederer, G Moll.   

Abstract

Monoamine oxidase-B (MAO-B) activity of platelets of an age- and sex-matched group of controls was compared with several groups of inpatients having non-familial dementia of Alzheimer type (DAT), Parkinson's disease (PD), multi-infarct dementia (MID), mixed types of these 3 diseases and a group of other central nervous system (CNS) organic disorders. All patients were subjected to several psychometric tests, including the Sandoz Clinical Assessment--Geriatric Scale, Hamilton Rating Scale for Depression, Mini-Mental State Examination and the Organic mental Disorder Scale (OMDS). A statistically significant enhancement of MAO-B activity could be observed in DAT patients and in PD patients, whereas the MID group showed a mean activity similar to that of the control group and the group with other organic CNS disorders. In DAT patients the degree of dementia in the OMDS test and the enhancement of MAO activity were positively correlated, but PD did not show such a correlation. It is concluded that the increase of MAO activity in PD and in DAT might be due to a disease-related enhanced affinity to oxygen and to such oxygen-derived radicals as superoxide or hydroxyl radicals. However, a possible drug-induced enhancement of MAO activity in PD cannot be excluded. Furthermore, the MAO-B activity values in platelets of individual patients or controls are not indicative of diagnosis or prognosis of any of these diseases and are of no disease-related specificity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3223331     DOI: 10.1111/j.1600-0447.1988.tb06412.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  13 in total

1.  Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy.

Authors:  G Finali; M Piccirilli; C Oliani; G L Piccinin
Journal:  Ital J Neurol Sci       Date:  1992-03

2.  Platelet monoamine oxidase B activity in parkinsonian patients.

Authors:  U Bonuccelli; P Piccini; P Del Dotto; G M Pacifici; G U Corsini; A Muratorio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

3.  Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication, and disease.

Authors:  Z Mészáros; D Borcsiczky; M Máté; J Tarcali; T Szombathy; K Tekes; K Magyar
Journal:  Neurochem Res       Date:  1998-06       Impact factor: 3.996

4.  Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.

Authors:  V Filip; E Kolibás
Journal:  J Psychiatry Neurosci       Date:  1999-05       Impact factor: 6.186

Review 5.  Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.

Authors:  Marco Bortolato; Jean C Shih
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

6.  Platelet monoamine oxidase B activity in workers exposed to styrene.

Authors:  H Checkoway; D Echeverria; J D Moon; N Heyer; L G Costa
Journal:  Int Arch Occup Environ Health       Date:  1994       Impact factor: 3.015

7.  Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.

Authors:  B Regland; C G Gottfries; L Oreland
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

8.  No changes in lymphocyte muscarinic receptors and platelet monoamine oxidase-B examined as surrogate central nervous system biomarkers in a Faroese children cohort prenatally exposed to methylmercury and polychlorinated biphenyls.

Authors:  Teresa Coccini; Luigi Manzo; Frodi Debes; Ulrike Steuerwald; Pal Weihe; Philippe Grandjean
Journal:  Biomarkers       Date:  2009-03       Impact factor: 2.658

9.  Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.

Authors:  Maroof Husain; Rakesh Shukla; Madhu Dikshit; Pradeep K Maheshwari; Devika Nag; Rikhab C Srimal; Prahlad K Seth; Vinay K Khanna
Journal:  Neurochem Res       Date:  2009-03-04       Impact factor: 3.996

10.  Application of Neurochemical Markers for Assessing Health Effects after Developmental Methylmercury and PCB Coexposure.

Authors:  E Roda; L Manzo; T Coccini
Journal:  J Toxicol       Date:  2012-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.